Zynerba Pharmaceuticals
$3.589876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$3.58
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
$0.00 (0.00%) Today
$0.00 (0.00%) As of 10:07 AM UTC after-hours
Why Robinhood?
You can buy or sell ZYNE and other stocks, options, and ETFs commission-free!
About ZYNE
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. It offers Zygel product which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA. The listed name for ZYNE is Zynerba Pharmaceuticals, Inc. Common Stock.
CEO
Armando Anido
Employees
28
Headquarters
Devon, Pennsylvania
Founded
2007
Market Cap
106.57M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.45M
High Today
$3.65
Low Today
$3.51
Open Price
$3.59
Volume
1.44M
52 Week High
$7.45
52 Week Low
$2.55
Collections
Analyst Ratings
71%
of 7 ratings
Buy
71%
Hold
29%
Sell
0%
ZYNE Earnings
-$0.78
-$0.52
-$0.26
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 9, Pre-Market